SCHEMBL10189279

SCHEMBL10189279

Cc1cc(-c2nscc2-c2ccc(OP(=O)(O)O)cc2)cc2c1OCO2

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRB2 P62993 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
PTGS2 P35354 1/20 0.31
BLM P54132 1/20 0.31
PRKCI P41743 1/20 0.31
PRKCZ Q05513 1/20 0.31
UGT1A1 P22309 1/20 0.30
UGT1A8 Q9HAW9 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL615454 0.88 KMT2A (0.42) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL10189273 0.85 ACHE (0.35) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL10189280 0.84 NPC1 (0.32) NPC1RAB9A
SCHEMBL10189278 0.83 UGT1A1 (0.41) MEN1KMT2APTGS2UGT1A1UGT1A8
SCHEMBL12339076 0.83 PTGS2 (0.32) GRB2MEN1KMT2APTGS2BLM
SCHEMBL10189275 0.82 EDNRB (0.37) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL10189274 0.79 CFTR (0.36) PTGS2RAB9AKDM4EALDH1A1LMNA
SCHEMBL10189256 0.79 FYN (0.33) KMT2ANPC1RAB9AKDM4EMAPT
SCHEMBL10189263 0.78 CYP2A6 (0.45)
SCHEMBL10189261 0.78 MAPT (0.39) MEN1KMT2ANPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 GRB2 1209/4885MEN1 1571/4885KMT2A 2808/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 GRB2 1209/4885MEN1 1571/4885KMT2A 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.